undamentalytics Newsletter
Sign in

Viking Therapeutics, Inc. income statement

In fiscal 2025, Viking Therapeutics, Inc. reported revenue of $0 and net income of −$360m, or −$3.19 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0000000000000
Research and development227914192432455464102345586
General and administrative15557911111637494862
Operating income−23−12−14−19−26−33−43−56−70−101−151−393−649
Income before tax—————————−86−110−360—
Income tax——0000000000—
Net income−22−23−15−21−22−26−39−55−69−86−110−360−627
Diluted EPS−$5.23−$3.68−$0.90−$0.79−$0.38−$0.36−$0.54−$0.71−$0.90−$0.91−$1.01−$3.19−$5.41
Diluted shares (average)4m6m16m26m58m72m73m77m77m94m109m113m116m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viking Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viking Therapeutics, Inc.